[SRNE] Sorrento Therapeutics, Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Commercial Physical & Biological Resarch

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 5.4 Change: 0.1 (1.89%)
Ext. hours: Change: 0 (0%)

chart SRNE

Refresh chart

Strongest Trends Summary For SRNE

SRNE is in the medium-term down -71% below S&P in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Sorrento Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. Its lead product candidate, Cynviloq, is a micellar diblock copolymeric paclitaxel formulation currently approved and marketed in various countries, including South Korea, for metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), and ovarian cancer under the trade name Genexol-PM. Cynviloq has also completed Phase I or III trials for MBC, and Phase I or II trials in NSCLC, Ovarian, Bladder, and Pancreatic cancers. The company is also developing resiniferatoxin, a non-opiate, ultra potent and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease. In addition, the company is also developing antibody drug conjugates and recombinant intravenous immunoglobulin (rIVIG) for the treatment of certain auto-immune diseases, as we

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 26.06% Sales Growth - Q/Q22.43% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-26.67% ROE-35% ROI
Current Ratio6.61 Quick Ratio Long Term Debt/Equity0.15 Debt Ratio0.09
Gross Margin48.01% Operating Margin-915.97% Net Profit Margin-914.85% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-710 K Cash From Investing Activities-1.84 M Cash From Operating Activities-8.85 M Gross Profit470 K
Net Profit-10.44 M Operating Profit-10.18 M Total Assets131.26 M Total Current Assets62.16 M
Total Current Liabilities9.4 M Total Debt13.13 M Total Liabilities31.26 M Total Revenue980 K
Technical Data
High 52 week9.95 Low 52 week2.01 Last close2.2 Last change4.76%
RSI57.83 Average true range0.13 Beta0.23 Volume208.25 K
Simple moving average 20 days0.41% Simple moving average 50 days-4.18% Simple moving average 200 days-51.63%
Performance Data
Performance Week-5.58% Performance Month1.85% Performance Quart-34.33% Performance Half-60.36%
Performance Year-73.81% Performance Year-to-date-8.33% Volatility daily4.31% Volatility weekly9.64%
Volatility monthly19.75% Volatility yearly68.4% Relative Volume488.97% Average Volume1.43 M
New High New Low


2019-03-22 15:01:06 | Analysts Give Favorable Opinions on Sorrento Therapeutics

2019-03-22 13:06:50 | Sorrento Therapeutics News: Why SRNE Stock Is On The Move

2019-03-22 07:00:00 | Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management

2019-03-11 07:00:00 | Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001

2019-02-25 07:00:00 | Sorrento Therapeutics to Present Corporate Update at Two Investor Conferences

2019-02-12 07:00:00 | Yuhan Corp and Sorrento Therapeutics Announce Closing of a $40m USD Financing for Joint Venture ImmuneOncia to Support Advancement of Immuno-Oncology Program

2019-02-08 09:06:39 | What Kind Of Shareholders Own Sorrento Therapeutics, Inc. NASDAQ:SRNE?

2019-01-31 08:20:00 | New Research: Key Drivers of Growth for Tapestry, FIS, News Corporation, Ollie's Bargain Outlet, Covanta Holding, and Sorrento Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

2019-01-22 09:30:00 | Health Stocks Benefitting the Most from Rally

2019-01-22 07:00:00 | Sorrento Therapeutics Announces Interim Results In Osteoarthritis Knee Pain Phase 1b Trial of Resiniferatoxin With Positive Therapeutic Signal and Absence of Dose Limiting Toxicities; Pivotal Trials Targeted to Start Later 2019

2019-01-14 07:00:00 | Scilex Announces ZTlido® Insurance Coverage for ~100 Million Insured Lives1

2019-01-14 07:00:00 | Scilex Announces Addition of ZTlido® to Express Scripts National Formularies

2019-01-04 07:00:00 | Dr. Henry Ji to Participate In Financing Expert Panel at East/West CEO Conference

2018-11-08 07:00:00 | Sorrento Therapeutics Closes Five-Year Term Loan Financing for Up to $150 Million

2018-11-06 08:01:00 | Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases

2018-11-01 07:00:00 | Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma

2018-10-25 08:10:00 | Research Report Identifies Sorrento Therapeutics, Hurco Companies, Veritiv, Park Electrochemical, VBI Vaccines, and PennantPark Floating Rate Capital with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2018-10-11 17:04:00 | Here's Why Sorrento Therapeutics Fell 20.7% in September

2018-10-05 14:16:05 | 10 Growth Stocks to Buy With Monster Potential

2018-10-01 08:00:00 | Scilex Announces the Availability of ZTlido™

2018-09-27 18:09:39 | Sorrento Therapeutics to Present at the Leerink Partners Roundtable Series 10/3/2018

2018-09-19 08:00:00 | Scilex Announces Pricing and Availability of ZTlido™ for the Commercial Launch of its First Product in October of 2018

2018-09-10 04:00:00 | Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido™ Pain Medication

2018-09-07 12:24:00 | Scilex Presents ZTlido™ Data on Superior Adhesion over Lidocaine Patch Formulation

2018-09-04 08:30:00 | Research Report Identifies Brady, Akari Therapeutics, MTGE Investment, Jones Lang LaSalle, New Relic, and Sorrento Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2018-09-02 13:19:38 | Sorrento Therapeutics to Present at FB Riley and HC Wainwright Sept 2018 Healthcare Conferences in NYC NY

2018-08-13 09:42:29 | Sorrento's Knee Pain Medication Found Safe, Effective Based On Early Data

2018-08-13 04:00:00 | 1st Patient Treated for Osteoarthritis Knee Pain in Sorrento Resiniferatoxin Phase 1B Trial Meets Both Safety and Efficacy Expectations

2018-07-23 08:10:00 | Today’s Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Sorrento Therapeutics

2018-07-23 07:05:00 | Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks

2018-07-05 17:32:37 | Why Clean Energy Fuels, Sorrento Therapeutics, and iQiyi Slumped Today

2018-07-05 16:11:00 | Why Sorrento Therapeutics, Inc. Stock Sank Today

2018-07-03 09:30:21 | Sorrento Acquires the Sofusa™ Lymphatic Delivery Platform for Immune-Oncology I-O Antibody Therapeutics

2018-06-26 07:15:00 | Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks

2018-06-14 16:42:50 | Sorrento Therapeutics issues Chairman/CEO corporate update to stockholders

2018-06-14 10:31:18 | Hong Kong market could open cash flood gates for U.S. biotechs

2018-05-25 07:10:00 | Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks

2018-05-24 19:47:24 | An Intrinsic Calculation For Sorrento Therapeutics Inc NASDAQ:SRNE Shows It’s 26% Undervalued

2018-05-11 08:30:00 | Consolidated Research: 2018 Summary Expectations for Sunstone Hotel Investors, Plains All American Pipeline, Sorrento Therapeutics, TD Ameritrade Holding, Meritor, and DXC Technology — Fundamental Analysis, Key Performance Indications

2018-05-08 08:30:00 | Today's Research Reports on Trending Tickers: Sorrento Therapeutics and Illumina

2018-04-24 13:43:00 | Lifshitz & Miller LLP Announces Investigation of Cancer Genetics, Inc., Colony Northstar, Inc., Pacific Commerce Bancorp, MiMedx Group, Inc., Sorrento Therapeutics, Inc., TrueCar, Inc., and Windstream Holdings, Inc.

2018-04-23 08:00:00 | Sorrento Therapeutics CEO Dr. Henry Ji Invited to the Fourth International Vatican Conference on “Unite to Cure”

2018-04-16 19:01:00 | Cramer's lightning round: Take a long-term view on Spotif...

2018-04-16 18:50:00 | Cramer's lightning round: Take a long-term view on Spotify

2018-04-05 14:53:03 | Sorrento and Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With Relapsed or Refractory Multiple Myeloma NCT03464916

2018-04-04 17:46:13 | Sorrento Therapeutics to Present at H.C. Wainwright Global Lifesciences Conference 04/09/18

2018-03-29 15:17:43 | Why the Sudden Surge in Sorrento Therapeutics’ Revenue?

2018-03-29 15:17:42 | Exploring Sorrento Therapeutics’ Research Pipeline

2018-03-29 15:17:42 | Analysts’ Ratings for Sorrento and Its Peers in March 2018

2018-03-28 19:28:13 | Sorrento Therapeutics Chairman/CEO update to stockholders